Sarah Cannon Cancer Center
Nashville, Tennessee, United States
Cancer treatment center in Nashville, Tennessee
2300 Patterson St, Nashville, TN 37203
About Sarah Cannon Cancer Center
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
20
Eli Lilly and Company
14
Novartis Pharmaceuticals
13
Celgene
11
Seagen Inc.
11
Genentech, Inc.
9
Adaptimmune
4
Favrille
4
Millennium Pharmaceuticals, Inc.
4
OSI Pharmaceuticals
4
Pfizer
4
Clinical Trials at Sarah Cannon Cancer Center
During the past decade, Sarah Cannon Cancer Center conducted 132 clinical trials. In the 10-year time frame, 132 clinical trials started and 52 clinical trials were completed, i.e. on
average, 39.4% percent of trials that started reached the finish line to date. In the past 5 years, 63 clinical trials started and 30 clinical trials were completed. i.e. 47.6%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer
1999-04-01
2011-02-01
Completed
605
Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma
2000-11-01
Unknown status
A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy
2001-02-01
2004-04-01
Completed
Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome
2002-04-01
2007-05-01
Completed
65
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
2001-11-29
2004-01-15
Completed
569
Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma
2002-07-01
Unknown status
90
Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy
2002-01-01
Completed
50
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
2002-09-01
2009-01-01
Completed
602
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Sarah Cannon Cancer Center" #1 sponsor was "Hoffmann-La Roche" with 20 trials, followed by "Eli Lilly and Company" with 14 trials
sponsored, "Novartis Pharmaceuticals" with 13 trials sponsored, "Celgene" with 11 trials sponsored and "Seagen Inc."
with 11 trials sponsored. Other sponsors include 158 different institutions and
companies that sponsored additional 111 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Sarah Cannon Cancer Center"
#1 collaborator was "Merck Sharp & Dohme LLC" with 11 trials as a collaborator, "National Cancer Institute (NCI)" with 9 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator, "Bayer" with 3 trials as a collaborator and "Bristol-Myers Squibb" with 2 trials as a collaborator. Other collaborators include 28 different institutions and companies that were
collaborators in the rest 33 trials.
Clinical Trials Conditions at Sarah Cannon Cancer Center
According to Clinical.Site data, the most researched conditions in "Sarah Cannon Cancer Center" are
"Breast Cancer" (20 trials), "Melanoma" (13 trials), "Colorectal Cancer" (10 trials), "Pancreatic Cancer" (10 trials) and "Cancer" (9 trials). Many other conditions were trialed in "Sarah Cannon Cancer Center" in a lesser frequency.
Clinical Trials Intervention Types at Sarah Cannon Cancer Center
Most popular intervention types in "Sarah Cannon Cancer Center" are "Drug" (197 trials), "Biological" (35 trials), "Other" (11 trials), "Procedure" (7 trials) and "Genetic" (4 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (18 trials), "Atezolizumab" (15 trials), "Paclitaxel" (10 trials), "Trastuzumab" (10 trials) and "Carboplatin" (9 trials). Other intervention names were less common.
Clinical Trials Genders at Sarah Cannon Cancer Center
The vast majority of trials in "Sarah Cannon Cancer Center" are
207 trials for "All" genders, 21 trials for "Female" genders and 4 trials for "Male" genders.
Clinical Trials Status at Sarah Cannon Cancer Center
Currently, there are NaN active trials in "Sarah Cannon Cancer Center".
undefined are not yet recruiting,
51 are recruiting,
48 are Active, not recruiting,
and 1 are Enrolling by invitation.
In total, there were 97 completed trials in Sarah Cannon Cancer Center,
undefined suspended trials,
and 27 terminated clinical trials to date.
Out of the total trials that were conducted in Sarah Cannon Cancer Center, 104 "Phase 1"
clinical trials were conducted, 111 "Phase 2" clinical
trials and 48 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 3 trials, and there were
also 1 trials that are defined as “Not Applicable".